Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
Abhelix LLC
Aduro BioTech Inc
Amgen Inc
AstraZeneca Plc
BioInvent Intertiol AB
BriaCell Therapeutics Corp
Cold Genesys Inc
Cytonus Therapeutics Inc
Epeius Biotechnologies Corp
GlaxoSmithKline Plc
Humabs BioMed SA
Humanigen Inc
I-Mab Biopharma Co Ltd
Iza Bioscience Ltd
Morphotek Inc
Seagull Labs (I) Pvt Ltd
Sillajen Biotherapeutics
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
Bria-IMT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bria-OTS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones
Featured News & Press Releases
Dec 17, 2019: BriaCell to present at Biotech Showcase 2020 in San Francisco
Dec 13, 2019: BriaCell announces clinical data as presented at the 2019 San Antonio Breast Cancer Symposium
Dec 11, 2019: Humanigen’s GM-CSF knockout data presented at the 2019 Annual Meeting of American Society of Hematology Receives Award
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Abhelix LLC, H1 2020
Pipeline by Aduro BioTech Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by BioInvent International AB, H1 2020
Pipeline by BriaCell Therapeutics Corp, H1 2020
Pipeline by Cold Genesys Inc, H1 2020
Pipeline by Cytonus Therapeutics Inc, H1 2020
Pipeline by Epeius Biotechnologies Corp, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Humabs BioMed SA, H1 2020
Pipeline by Humanigen Inc, H1 2020
Pipeline by I-Mab Biopharma Co Ltd, H1 2020
Pipeline by Izana Bioscience Ltd, H1 2020
Pipeline by Morphotek Inc, H1 2020
Pipeline by Seagull Labs (I) Pvt Ltd, H1 2020
Pipeline by Sillajen Biotherapeutics, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020